-
ExeGi Pharma Grants Dogs Long-Overdue Institutional Recognition
Canine colleagues receive their own policy, calendar and official place in corporate life
-
ExeGi Pharma Celebrates 25th Anniversary of Landmark De Simone Formulation
Rockville, Md. – ExeGi Pharma, a biotechnology company specializing in live biotherapeutics, today announced the 25th anniversary of the De Simone Formulation, a high potency probiotic blend that has transformed the landscape of gastrointestinal care. The formulation first gained clinical prominence in August 2000, when Professor Paolo Gionchetti and colleagues published a landmark study demonstrating…
-
ExeGi Pharma Positive Topline Results in EXE-346 PROF Phase 1b Study
ROCKVILLE, Md., Dec. 17, 2024 /PRNewswire/ — ExeGi Pharma LLC, a company focused on developing live biotherapeutic (“LBP”) drugs and probiotics, announced positive topline results in the Phase 1b portion of its PROF study. The PROF study is designed to investigate EXE-346 in patients with an ileal pouch-anal anastomosis (IPAA, or “J-pouch”) who experience excessive stool frequency. EXE-346 is…
-
De Simone Formulation Named in AGA Clinical Practice Guidelines on Management of Pouchitis and Inflammatory Pouch Disorders
Pouchitis is an inflammatory condition that may occur in patients who have undergone an ileal pouch anal anastomosis (IPAA). The symptoms associated with pouchitis can be debilitating for patients and treatment options, especially for those who have symptoms resistant to antibiotics, are limited. The De Simone Formulation found only in Visbiome high potency probiotics, was…
-
Visbiome GI Care High Potency Capsules Now Certified By The Clean Label Project®
Rockville, MD – ExeGi Pharma LLC, a leader in digestive health solutions, is proud to announce that its flagship product, Visbiome GI Care Probiotic Capsules, has achieved the prestigious Clean Label Project® Certification and Clean Label Project Pesticide Free Certification. The Clean Label Project is a national nonprofit consumer advocacy and standards development organization focused on…
-
ExeGi Pharma Announces Partnership With TannerLAC to Bring Visbiome® High Potency Probiotic to Mexico
Rockville, M.D., and Charlotte, N.C., April 12, 2023 – ExeGi Pharma LLC (“ExeGi”), a leading developer of live biotherapeutic drugs and probiotics, has announced a partnership with TannerLAC, Inc. (“TannerLAC”), a division of Tanner Pharma Group, to distribute Visbiome in Mexico. Visbiome is a high potency probiotic medical food designed to manage microbial imbalances associated with medical conditions…
-
Visbiome Probiotic Prevails In Landmark False Advertising Lawsuit Against Competitor Brookfield Pharmacuticals
April 5, 2023 – ExeGi Pharma, LLC, owner of the Visbiome probiotic, has secured a significant legal victory against Brookfield Pharmaceuticals, LLC. ExeGi alleged that Brookfield engaged in false advertising and unfair competition by promoting its High Potency Probiotic (“HPP”) as a generic equivalent of Visbiome. The United States District Court for the Eastern District of Wisconsin ruled in favor of ExeGi, entering summary judgment and…
-
ExeGi Pharma Announces Clearance of Investigational New Drug (IND) Application for EXE-346 a Live Biotherapeutic Biologic Drug
Rockville, MD – January 26th, 2023 ExeGi Pharma LLC, a leader in the development of live biotherapeutic drugs and probiotics, announced today that the FDA has cleared its Investigational New Drug (IND) application for its biologic drug candidate, EXE-346. This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal…
-
FDA Orphan Drug Designation for EXE-346 Live Biotherapeutic
November 12, 2020 (Rockville, Maryland): ExeGi Pharma LLC, a company focused on developing live biotherapeutic (“LBP”) drugs and probiotics, announced today that its biologic drug candidate, EXE-346, has received an orphan drug designation from the U.S. Food and Drug Administration (FDA) for the prevention of disease relapse in pouchitis. This designation grants certain benefits to…
-
First Published Clinical Trial Using Live Biotherapeutic Candidate in COVID-19 Patients Suggests Role In Improving Outcome
ROCKVILLE, Md., July 13, 2020 ExeGi Pharma LLC, a U.S.-based company focused on developing and commercializing products targeting the human microbiome, including live biotherapeutic products (LBPs), announced today the results of a 70-patient clinical trial evaluating a new biologic drug candidate in hospitalized COVID-19 patients. The study was conducted in a hospital setting in Rome…
-
ExeGi Wins Court Ruling Against VSL#3®*, Permanent Injunction Blocks False Advertising To Doctors, Consumers
Federal district court finds in favor of ExeGi and probiotic inventor, prohibits VSL#3 sellers from citing studies on original formulation ROCKVILLE, Md., June 25, 2019 /PRNewswire/ — ExeGi Pharma LLC is pleased to announce that on Friday, June 21, the United States District Court for the District of Maryland ruled in favor of a probiotic inventor and his business partner, ExeGi Pharma, LLC,…
-
Maryland Federal Jury Unanimously Finds Probiotic Sellers Liable for False Advertising and Awards Product Inventor More than $18 Million in Damages
Claudio De Simone, inventor of high-potency probiotic, sued pharmaceutical companies for making false advertising claims, ownership rights to the product formula and unpaid royalties November 26, 2018 09:30 AM Eastern Standard Time GREENBELT, Md. – A federal jury on Tuesday, Nov. 20, unanimously ruled in favor of a probiotic inventor who sued his former business…
-
EXEGI PHARMA LAUNCHES HIGH POTENCY VETERINARY PROBIOTIC
Clinical studies show a probiotic used to manage human GI disorders can help support bowel and gut health in dogs. ExeGi Pharma Launches a high potency veterinary probiotic for companion animals. ROCKVILLE, MD ExeGi Pharma LLC, a company focused on developing and commercializing live biotherapeutics and probiotic treatments, announced today the new Visbiome ® Vet.…
-
Visbiome Probiotic May Play a Role in Recovery of GI Functions in HIV Patients
http://www.businesswire.com/news/home/20170502006014/en/Multi-Strain-Probiotic-Play-Role-Recovery-Critical-Gastrointestinal ROCKVILLE, Md.–(BUSINESS WIRE)–A newly released study published in the Journal ofImmunity, Inflammation and Disease and conducted by the Sapienza University of Rome, Italy, found a multi-strain, high concentration, probiotic formulation that helped reconstitute the physical and immunological integrity of the gastrointestinal lining in HIV-1-positive patients on antiretroviral therapy (ART). The human gastrointestinal (GI) tract is…
-
ExeGi Pharma Recognizes World AIDS Day
ROCKVILLE, MD., Dec. 1, 2016– December 1st marks the observation of the 28th World AIDS Day, a day dedicated to the fight against HIV, those who have lost their lives to AIDS, and those currently living with HIV. ExeGi Pharma recognizes World AIDS Day and reaffirms its commitment to the research of Visbiome, a high…
